Opinion|Videos|October 21, 2024

Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

Key Takeaways

Neal Shore, MD, FACS, discusses the evolving use of follow-up PSMA PET scans and the recent FORE trial, which showed that Lutetium-177 improves radiographic progression-free survival and PSA levels in prechemotherapy patients with mCRPC, with more data on overall survival and quality of life expected.